<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="28790">5-HT</z:chebi>(4) receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>, and gastrointestinal (GI) prokinetic agents, cisapride and <z:chebi fb="0" ids="51043">tegaserod</z:chebi>, lack selectivity for the <z:chebi fb="0" ids="28790">5-HT</z:chebi>(4) receptor </plain></SENT>
<SENT sid="1" pm="."><plain>Cisapride is a potent human <z:chebi fb="91" ids="25698">ether</z:chebi>-Ã -go-go-related gene (hERG) <z:chebi fb="120" ids="26216">potassium</z:chebi> channel inhibitor while cisapride and <z:chebi fb="0" ids="51043">tegaserod</z:chebi> have significant affinity for <z:chebi fb="0" ids="28790">5-HT</z:chebi>(1) and <z:chebi fb="0" ids="28790">5-HT</z:chebi>(2) receptor subtypes </plain></SENT>
<SENT sid="2" pm="."><plain>Marketing of both compounds was discontinued due to cardiovascular concerns (<z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> with cisapride and ischemic events with <z:chebi fb="0" ids="51043">tegaserod</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>The reported association of <z:chebi fb="0" ids="51043">tegaserod</z:chebi> with <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> has been postulated to involve coronary artery constriction or augmentation of platelet aggregation </plain></SENT>
<SENT sid="4" pm="."><plain>This in vitro study investigated the effects of two of the new generation of highly selective <z:chebi fb="0" ids="28790">5-HT</z:chebi>(4) receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>, velusetrag and TD-8954, on canine, porcine and human coronary artery tone, human platelet aggregation and hERG <z:chebi fb="120" ids="26216">potassium</z:chebi> channel conductance </plain></SENT>
<SENT sid="5" pm="."><plain>No significant off-target actions of velusetrag or TD-8954 were identified in these, and prior, studies </plain></SENT>
<SENT sid="6" pm="."><plain>While cisapride inhibited potently the hERG channel currents, <z:chebi fb="0" ids="51043">tegaserod</z:chebi> failed to affect platelet aggregation, and had only a small contractile effect on the canine coronary artery at high concentrations </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="51043">Tegaserod</z:chebi> inhibited the <z:chebi fb="0" ids="28790">5-HT</z:chebi>-induced contractile response in the porcine coronary artery </plain></SENT>
<SENT sid="8" pm="."><plain>New generation <z:chebi fb="0" ids="28790">5-HT</z:chebi>(4) receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> hold promise for the treatment of patients suffering from GI motility disorders with a reduced cardiovascular risk </plain></SENT>
</text></document>